SCHEMBL1618007

SCHEMBL1618007

COc1ccc(CCOc2nc(NN=Cc3c[nH]c4ccccc34)cc(N3CCOCC3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIKFYVE Q9Y2I7 2/20 0.51
TYK2 P29597 2/20 0.51
SYK P43405 2/20 0.51
IRAK4 Q9NWZ3 2/20 0.51
FES P07332 1/20 0.51
FER P16591 1/20 0.51
FRK P42685 1/20 0.51
CAMK1D Q8IU85 1/20 0.51
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
MAPT P10636 8/20 0.48
GAA P10253 3/20 0.48
ALDH1A1 P00352 1/20 0.48
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425001 0.91 PIKFYVE (0.50) PIKFYVETYK2SYKIRAK4FES
SCHEMBL10197075 0.91 PIKFYVE (0.50) PIKFYVETYK2SYKIRAK4FES
SCHEMBL425002 0.91 PIKFYVE (0.50) PIKFYVETYK2SYKIRAK4FES
SCHEMBL13333736 0.89 PIKFYVE (0.48) PIKFYVETYK2SYKIRAK4FES
SCHEMBL426317 0.88 L3MBTL1 (0.56) PIKFYVETYK2SYKIRAK4FES
SCHEMBL10198704 0.88 L3MBTL1 (0.56) PIKFYVETYK2SYKIRAK4FES
SCHEMBL426316 0.88 L3MBTL1 (0.56) PIKFYVETYK2SYKIRAK4FES
SCHEMBL428496 0.85 TYK2 (0.68) PIKFYVETYK2SYKIRAK4FES
SCHEMBL428497 0.85 TYK2 (0.68) PIKFYVETYK2SYKIRAK4FES
SCHEMBL10198709 0.85 TYK2 (0.68) PIKFYVETYK2SYKIRAK4FES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923557-B2 Process for preparing trisubstituted pyrimidine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2011-04-12 US disclosed
US-20060122209-A1 Process for preparing trisubstituted pyrimidine compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122209-A1 Process for preparing trisubstituted pyrimidine compounds TYMS, NUDT1, TYMP PIKFYVE 2300/4885TYK2 1701/4885SYK 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.